Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Anemia, Unexplained Anemia (UAE)
Interventions: iron sucrose; Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Social Determinants of Health (SDOH)
Interventions: Survey using a questionnaire.; Other
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
Interventions: Ferumoxytol, Oral Iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Cyanotic Congenital Heart Disease, Anemia, Cyanosis, Congenital Heart Disease
Interventions: Epoetin Alfa and Iron, Iron; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 8 Weeks
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more

Conditions: End Stage Renal Disease, Anemia
Interventions: Roxadustat, Epoetin Alfa, Placebo; Drug · Other
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more

Conditions: Nutritional Deficiency
Interventions: Study 1: Whey Supplement Day 1, Study 1: Whey Supplement Day 2, Study 2: Whey Supplement; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 3 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperphosphatemia
Interventions: PA21 (Velphoro®), Calcium Acetate (Phoslyra®); Drug
Lead sponsor: Vifor Fresenius Medical Care Renal Pharma; Industry
Eligibility: Up to 18 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 17 more

Conditions: Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Refractory Cancer
Interventions: VLX600; Drug
Lead sponsor: Vivolux AB; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Hypothermia
Interventions: Air-Activated heating packs, Forced Air Warming Device; Device
Lead sponsor: Dr K Services PC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: COVID-19
Interventions: chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract; Other · Dietary Supplement · Drug
Lead sponsor: Profact, Inc.; Other
Eligibility: 20 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) - Refractory
Interventions: CliniMACS System; Device
Lead sponsor: Ginna Laport; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hookworm Infection, Hookworm Disease
Interventions: 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Stroke, Problem of Aging
Interventions: desferrioxamine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: Deferiprone oral solution, Placebo; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 4 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acute Mountain Sickness
Interventions: Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride; Drug
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Leadville, Colorado • Eugene, Oregon

Conditions: Cancer, Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation
Interventions: magnetic resonance imaging, Serum ferritin; Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Iron Deficiency Anemia
Interventions: Ferrous Sulfate Oral Product; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 29 Weeks to 33 Weeks
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Liver Diseases
Interventions: Magnetic Resonance Imaging (MRI); Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Orleans, Louisiana • Memphis, Tennessee

Conditions: Iron Deficiency Anemia (IDA)
Interventions: Not listed
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Overload, Hereditary Hemochromatosis
Interventions: Deferasirox (ICL670); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Long Beach, California • Farmington, Connecticut • Detroit, Michigan + 6 more

Search by objective public record fields.

Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

Effects of Social Determinants of Health on IV Iron Treatments

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet

A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

Efficacy of Warming Garment in the Perioperative Period With Integrated Chemical Heat Packs to Maintain Normothermia

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

Haploid Allogeneic Transplant Using the CliniMACS System

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

Modulation of Cerebral Blood Flow Using Iron Chelators

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Colorado-Oregon Altitude Study

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

Donor Breast Milk 2

Liver Fat and Iron Quantification MRI

Sickle Cell Disease: A Retrospective Chart Review

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis